Cardiomyocyte A Disintegrin and Metalloproteinase 17 (ADAM17) Is Essential in Post-Myocardial Infarction Repair by Regulating Angiogenesis

Circulation: Heart Failure

Volumn 8, Issue 5, 2015, Pages 970-979

  Fan, Dong ^a   Takawale, Abhijit ^a   Shen, Mengcheng ^a   Wang, Wang ^a,b   Wang, Xiuhua ^a   Basu, Ratnadeep ^a,b   Oudit, Gavin Y ^b   Kassiri, Zamaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Division of Cardiology   (United States)

Author keywords

Cardiac remodeling; inflammation; myocardial infarction; tumor necrosis factor alpha convertase; vascular endothelial growth factor receptor 2

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 17; COLLAGENASE 3; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 28; MEMBRANE ENZYME; MESSENGER RNA; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ADAM PROTEIN; RNA; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DNA BINDING; EX VIVO STUDY; FIBROBLAST; GENE EXPRESSION; GENE SILENCING; GENOTYPE; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART RUPTURE; IN VITRO STUDY; INFLAMMATION; ISCHEMIC CARDIOMYOPATHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; UPREGULATION; ANIMAL; BIOSYNTHESIS; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; HEART VENTRICLE REMODELING; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ADAM PROTEINS; ANIMALS; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PATHOLOGIC; RNA; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 84953344999     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.002029     Document Type: Article

References (38)

1. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729-733. doi: 10.1038/385729a0.
2. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385:733-736. doi: 10.1038/385733a0.
3. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011;32:380-387. doi: 10.1016/j.it.2011.05.005.
4. Satoh M, Nakamura M, Satoh H, Saitoh H, Segawa I, Hiramori K. Expression of tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human myocarditis. J Am Coll Cardiol. 2000;36:1288-1294.
5. Fedak PW, Moravec CS, McCarthy PM, Altamentova SM, Wong AP, Skrtic M, Verma S, Weisel RD, Li RK. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation. 2006;113:238-245. doi: 10.1161/CIRCULATIONAHA.105.571414.
6. Shimoda Y, Satoh M, Nakamura M, Akatsu T, Hiramori K. Activated tumour necrosis factor-alpha shedding process is associated with in-hospital complication in patients with acute myocardial infarction. Clin Sci (Lond). 2005;108:339-347. doi: 10.1042/CS20040229.
7. Satoh M, Ishikawa Y, Itoh T, Minami Y, Takahashi Y, Nakamura M. The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. Eur J Clin Invest. 2008;38:97-105. doi: 10.1111/j.1365-2362.2007.01912.x.
8. Akatsu T, Nakamura M, Satoh M, Hiramori K. Increased mRNA expression of tumour necrosis factor-alpha and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction. Clin Sci (Lond). 2003;105:39-44. doi: 10.1042/CS20020367.
9. Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS. Tumor necrosis factor-?: investigation of gene polymorphism and regulation of TACE-TNF-? system in patients with acute myocardial infarction. Mol Biol Rep. 2011;38:4971-4977. doi: 10.1007/s11033-010-0641-x.
10. Satoh M, Iwasaka J, Nakamura M, Akatsu T, Shimoda Y, Hiramori K. Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure. Eur J Heart Fail. 2004;6:869-875. doi: 10.1016/j.ejheart.2004.02.007.
11. Helisch A, Ware JA. Therapeutic angiogenesis for ischemic heart disease. Adv Exp Med Biol. 2000;476:327-350.
12. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981-2988.
13. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298-307. doi: 10.1038/nature10144.
14. Caolo V, Swennen G, Chalaris A, Wagenaar A, Verbruggen S, Rose-John S, Molin DG, Vooijs M, Post MJ. ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis. Angiogenesis. 2015;18:13-22. doi: 10.1007/s10456-014-9443-4.
15. Das S, Czarnek M, Bzowska M, Myk-Kope? R, Staliska K, Wyroba B, Sroka J, Jucha J, Deneka D, Stok?osa P, Ogonek J, Swartz MA, Madeja Z, Bereta J. ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis. PLoS One. 2012;7:e50791. doi: 10.1371/journal.pone.0050791.
16. Lin J, Lemke C, Redies C, Yan X, Mix E, Rolfs A, Luo J. ADAM17 overexpression promotes angiogenesis by increasing blood vessel sprouting and pericyte number during brain microvessel development. Int J Dev Biol. 2011;55:961-968. doi: 10.1387/ijdb.103210jl.
17. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S, Hinoki A, Eguchi S, Guaiquil V, Horiuchi K, Blobel CP. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res. 2010;106:932-940. doi: 10.1161/CIRCRESAHA.109.207415.
18. Lucitti JL, Mackey JK, Morrison JC, Haigh JJ, Adams RH, Faber JE. Formation of the collateral circulation is regulated by vascular endothelial growth factor-A and a disintegrin and metalloprotease family members 10 and 17. Circ Res. 2012;111:1539-1550. doi: 10.1161/CIRCRESAHA.112.279109.
19. Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, Toyama Y, Blobel CP. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol. 2007;179:2686-2689.
20. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z. TIMP2 deficiency accelerates adverse postmyocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res. 2010;106:796-808. doi: 10.1161/CIRCRESAHA.109.209189.
21. Wang W, McKinnie SM, Patel VB, Haddad G, Wang Z, Zhabyeyev P, Das SK, Basu R, McLean B, Kandalam V, Penninger JM, Kassiri Z, Vederas JC, Murray AG, Oudit GY. Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc. 2013;2:e000249. doi: 10.1161/JAHA.113.000249.
22. Takawale A, Fan D, Basu R, Shen M, Parajuli N, Wang W, Wang X, Oudit GY, Kassiri Z. Myocardial recovery from ischemia-reperfusion is compromised in the absence of tissue inhibitor of metalloproteinase 4. Circ Heart Fail. 2014;7:652-662. doi: 10.1161/CIRCHEARTFAILURE.114.001113.
23. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ, Oudit GY. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014;66:167-176. doi: 10.1016/j.yjmcc.2013.11.017.
24. Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, Oudit GY, Kassiri Z. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation. 2011;124:2094-2105. doi: 10.1161/CIRCULATIONAHA.111.030338.
25. Fan D, Takawale A, Basu R, Patel V, Lee J, Kandalam V, Wang X, Oudit GY, Kassiri Z. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc Res. 2014;103:268-280. doi: 10.1093/cvr/cvu072.
26. Iyer RP, de Castro Brás LE, Jin YF, Lindsey ML. Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res. 2014;114:860-871. doi: 10.1161/CIRCRESAHA.114.301673.
27. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC. VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One. 2011;6:e25668. doi: 10.1371/journal.pone.0025668.
28. Cui XB, Guo X, Chen SY. Response gene to complement 32 deficiency causes impaired placental angiogenesis in mice. Cardiovasc Res. 2013;99:632-639. doi: 10.1093/cvr/cvt121.
29. Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, Federici M, Sibilia M, Blobel CP, Khokha R. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest. 2010;120:2731-2744. doi: 10.1172/JCI42686.
30. Sisto M, Lisi S, Lofrumento DD, D'Amore M, Frassanito MA, Ribatti D. Sjögren's syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-?B. Genes Immun. 2012;13:411-420. doi: 10.1038/gene.2012.9.
31. Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, Scherle P, Hooper A, Rafii S, Blobel CP. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res. 2008;103:916-918. doi: 10.1161/CIRCRESAHA.108.184416.
32. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res. 2001;88:167-174.
33. Kattman SJ, Huber TL, Keller GM. Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev Cell. 2006;11:723-732. doi: 10.1016/j.devcel.2006.10.002.
34. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knaüper V, Docherty AJ, Murphy G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435:39-44.
35. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000;12: 85-98. doi: 10.1006/smim.2000.0210.
36. Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem. 1995;270:23111-23118.
37. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol. 2004;164:769-779. doi: 10.1083/jcb.200307137.
38. Liu C, Xu P, Lamouille S, Xu J, Derynck R. TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. Mol Cell. 2009;35:26-36. doi: 10.1016/j.molcel.2009.06.018.